# Consolidated Financial Results <br> for the Three Months Ended May 31, 2023 [Japanese GAAP] 

July 10, 2023
Company name: WELCIA HOLDINGS CO., LTD.
Stock exchange listing: Tokyo Stock Exchange
Code number: 3141
URL: https://www.welcia.co.jp/
Representative: Tadahisa Matsumoto, President and Representative Director
Contact: Takamune Shibazaki, Director, Executive Officer and Chief Financial Officer
Phone: +81-3-5207-5878
Scheduled date of filing quarterly securities report: July 10, 2023
Scheduled date of commencing dividend payments: -
Availability of supplementary briefing material on quarterly financial results: Available
Schedule of quarterly financial results briefing session: Scheduled (for institutional investors)
(Amounts of less than one million yen are rounded down.)

1. Consolidated Financial Results for the Three Months Ended May 31, 2023 (March 1, 2023 - May 31, 2023)
(1) Consolidated Operating Results (cumulative) ( $\%$ indicates changes from the previous corresponding period.)

|  | Net sales |  | Operating income | Ordinary income | Net income <br> attributable to <br> owners of parent |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: |
| Three months ended | Million yen | $\%$ |  | $\%$ | Million yen | $\%$ | Million yen | $\%$ |
| May 31, 2023 | 298,267 | 11.4 | 7,381 | $(4.3)$ | 8,524 | $(18.8)$ | 5,126 | $(18.9)$ |
| May 31, 2022 | 267,716 | 7.6 | 7,713 | 5.9 | 10,495 | 18.6 | 6,321 | 19.1 |

(Note) Comprehensive income: Three months ended May 31, 2023: $¥ 5,160$ million [(20.2)\%]
Three months ended May 31, 2022: $¥ 6,464$ million [22.4\%]

|  | Net income <br> per share |  |
| :--- | ---: | ---: |
| Diluted net income <br> per share |  |  |
| Three months ended | 24.56 | Yen |
| May 31, 2023 | 30.30 | 24.54 |
| May 31, 2022 | 30.28 |  |

(2) Consolidated Financial Position

|  | Total assets | Net assets | Equity ratio |
| :--- | ---: | ---: | ---: |
|  | Million yen | Million yen | $\%$ |
| As of May 31, 2023 | 546,266 | 226,575 | 40.2 |
| As of February 28, 2023 | 537,362 | 232,384 | 42.0 |

(Reference) Equity: As of May 31, 2023: $¥ 219,643$ million
As of February 28, 2023: $¥ 225,750$ million
2. Dividends

|  | Annual dividends |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: |
|  | 1st quarter-end | 2nd quarter-end | 3rd quarter-end | Year-end | Total |
| Fiscal year ended <br> February 28, 2023 <br> Fiscal year ending <br> February 29, 2024 | Yen | Yen | Yen | Yen | Yen |
| Fiscal year ending <br> February 29, 2024 <br> (Forecast) | - | 16.00 | - | 16.00 | 32.00 |

(Note) Revision to the forecast for dividends announced most recently: None
3. Consolidated Financial Results Forecast for the Fiscal Year Ending February 29, 2024 (March 1, 2023 February 29, 2024)

|  | Net sales |  | Operating income |  | Ordinary income |  | Net incomeattributable to owners of parent |  | Net income per share |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Million yen | \% | Million yen | \% | Million yen | \% | Million yen | \% | Yen |
| Six months ending August 31, 2023 | 612,220 | 8.8 | 25,740 | 7.3 | 28,030 | 0.2 | 16,700 | (2.3) | 79.82 |
| Full year | 1,230,000 | 7.5 | 48,000 | 5.2 | 52,500 | 0.7 | 28,000 | 3.6 | 133.83 |

(Note) Revision to the financial results forecast announced most recently: None

## * Notes:

(1) Changes in significant subsidiaries during the period under review: None
(Changes in specified subsidiaries resulting in changes in scope of consolidation):
Newly included: - ( ), Excluded: - ( )
(2) Accounting methods adopted particularly for the preparation of quarterly consolidated financial statements: None
(3) Changes in accounting policies, changes in accounting estimates and retrospective restatement

1) Changes in accounting policies due to the revision of accounting standards: None
2) Changes in accounting policies other than 1) above: None
3) Changes in accounting estimates: None
4) Retrospective restatement: None
(4) Total number of issued and outstanding shares (common shares)
5) Total number of issued and outstanding shares at the end of the period (including treasury stock):

May 31, 2023:
February 28, 2023:

209,656,076 shares
209,652,876 shares
2) Total number of treasury stock at the end of the period:

May 31, 2023 :
$3,077,729$ shares
February 28, 2023: 425,469 shares
3) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year):

Three months ended May 31, 2023:
208,732,925 shares
Three months ended May 31, 2022:
$208,639,189$ shares
(Notes) The number of shares of the Company held in the Employees' Stock Ownership ESOP Trust (May 31, 2023: $2,652,100$ shares) and the number of shares of the Company held in the Directors' Remuneration BIP Trust (February 28, 2023: 412,219 shares; May 31, 2023: 412,219 shares) were included in the total number of treasury stock at the end of the period. The number of shares of the Company held in the Employees' Stock Ownership ESOP Trust was included in the number of treasury stock, which was to be deducted from the calculation of the average number of shares outstanding during the period (May 31, 2022: 981,682 shares; May 31, 2023: 907,032 shares).

* These quarterly consolidated financial results are outside the scope of quarterly review by certified public accountants or an audit firm.
* Explanation of the proper use of financial results forecast and other notes

The earnings forecasts and other forward-looking statements provided herein are based on information available to the Company and certain assumptions deemed reasonable, and the Company does not promise the achievement of those forecasts. Actual results may differ significantly from these forecasts due to a wide range of factors. For the assumptions underlying the forecasts and the notes on the use of the forecasts, please refer to " 1 . Qualitative Information on Quarterly Financial Results (3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information" on page 4 of the attached document.

1. Qualitative Information on Quarterly Financial Results ..... 2
(1) Explanation of Operating Results ..... 2
(2) Explanation of Financial Position ..... 4
(3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information ..... 4
2. Quarterly Consolidated Financial Statements and Principal Notes ..... 5
(1) Quarterly Consolidated Balance Sheets ..... 5
(2) Quarterly Consolidated Statements of Income and Comprehensive Income ..... 7
Quarterly Consolidated Statements of Income Three Months Ended May 31 ..... 7
Quarterly Consolidated Statements of Comprehensive Income Three Months Ended May 31 ..... 8
(3) Notes to Quarterly Consolidated Financial Statements ..... 9
(Notes on going concern assumption) ..... 9
(Notes in case of significant changes in shareholders' equity) ..... 9
(1) Explanation of Operating Results

During the three months ended May 31, 2023 (from March 1, 2023 to May 31, 2023), signs of gradual resumption of social and economic activities became evident, as the severe impact of the COVID-19 pandemic eased, the disease itself was downgraded to a Class V Infectious Disease and the flow of people picked up both in Japan and overseas.

However, the outlook for the Japanese economy remains uncertain with the prolonged situation in Ukraine and the rise in consumer prices, which was caused by soaring energy and raw material prices.

In the drugstore industry, the primary area of the Group's business, the business environment surrounding the Company continues to be increasingly challenging due to such factors as the competition for new store sites with the competitors, major players expanding their scales of business through mergers and acquisitions, and the expansion of customer services involving players from across different industrial sectors and business formats. In terms of product trends, demand for COVID-19 infection control products has declined along with the decrease in infections. On the other hand, there are signs of recovery in cosmetics, reflecting increased opportunities for people going out, and in inbound demand, reflecting the relaxation of behavioral restrictions in many countries.

Under such circumstances, the Group strove to provide products and services in response to customer needs. In sales of goods, despite the reactionary drop in sales of products such as masks and test kits, which had climbed during the COVID-19 pandemic, existing store sales remained solid as a result of increasing demand associated with people going out. In the dispensing division, the number of prescriptions handled increased due primarily to an increase in the number of stores with dispensing pharmacies (2,044 stores as of May 31, 2023). Furthermore, in terms of product development, the Group continued to focus on the development of its PB products and strove to expand the sales of Karada Welcia and Kurashi Welcia. The Group also stepped up its measures to attract customers by introducing the WAON POINT service in March 2023 and allowing customers to use both WAON POINT cards and T-POINT cards, which had been adopted earlier. The Group also managed to optimize selling, general and administrative expenses, by improving store operational efficiency primarily through initiatives to reduce energy consumption at the stores and the promotion of automatic ordering, although utilities expenses were significantly increased by soaring fuel prices.

As for store openings and closures, the Group as a whole opened 38 stores and closed 10 stores, for a total of 2,791 stores Group-wide as of May 31, 2023.
(Unit: No. of Stores)

|  | No. of stores as of <br> February 28, 2023 | Openings | Closures | No. of stores as of <br> May 31, 2023 |
| :--- | ---: | ---: | ---: | ---: |
| WELCIAYAKKYOKU | 2,145 | 31 | 6 | 2,170 |
| Kokumin | 156 | 1 | 2 | 155 |
| Pupule Himawari | 134 | - | - | 134 |
| Marudai Sakurai <br> Pharmacy | 96 | 2 | - | 98 |
| SHIMIZU YAKUHIN | 68 | 1 | - | 69 |
| Marue Drug | 60 | - | 1 | 59 |
| Fukuyakuhin | 25 | 1 | - | 26 |
| YODOYA | 25 | - | - | 25 |
| French | 3 | - | - | 3 |
| MASAYA | 39 | 1 | 9 | 40 |
| Total in Japan | 2,751 | 12 | 1 | 1 |

(Notes) Of the number of stores as of May 31, 2023, 1,832 stores of WELCIA YAKKYOKU, 51 stores of Kokumin, 21 stores of Pupule Himawari, 42 stores of Marudai Sakurai Pharmacy, 45 stores of SHIMIZU YAKUHIN, 28 stores of Marue Drug, 10 stores of Fukuyakuhin, 10 stores of YODOYA, and 5 stores of Welcia-BHG (Singapore) have dispensing pharmacies, or a total of 2,044 stores have dispensing pharmacies. Of the same number, 1,737 stores of WELCIA YAKKYOKU, 3 stores of Kokumin, 74 stores of Pupule Himawari, 49 stores of Marudai Sakurai Pharmacy, 62 stores of SHIMIZU YAKUHIN, 24 stores of Marue Drug, 17 stores of Fukuyakuhin, and 14 stores of YODOYA offer late-night services, or a total of 1,980 stores offer late-night services.

Sales by category were as indicated below.

| Category | Sales (million yen) | Year-on-year change (\%) |
| :---: | :---: | :---: |
| OTC products | 56,942 | 108.3 |
| Cosmetics | 46,768 | 112.7 |
| Household goods | 39,640 | 107.0 |
| Food products | 67,238 | 111.3 |
| Others | 23,915 | 108.5 |
| Total sales of goods other than dispensing | 234,506 | 109.8 |
| Dispensing | 63,313 | 117.6 |
| Subtotal | 297,819 | 111.4 |
| Commission income | 447 | 151.6 |
| Total | 298,267 | 111.4 |

As a result of the above, the consolidated operating results for the three months ended May 31, 2023, were $¥ 298,267$ million in net sales (an increase of $11.4 \%$ year-on-year), $¥ 7,381$ million in operating income (a decrease of $4.3 \%$ year-on-year), $¥ 8,524$ million in ordinary income (a decrease of $18.8 \%$ year-on-year), and $¥ 5,126$ million in net income attributable to owners of parent (a decrease of $18.9 \%$ year-on-year).
(2) Explanation of Financial Position
(Assets)
Total assets as of May 31, 2023 increased by $¥ 8,904$ million compared to the end of the previous fiscal year to $¥ 546,266$ million. This was primarily due to increases of $¥ 4,567$ million in cash and deposits, $¥ 9,660$ million in merchandise, and $¥ 1,770$ million in buildings and structures, net.

## (Liabilities)

Total liabilities as of May 31, 2023 increased by $¥ 14,713$ million compared to the end of the previous fiscal year to $¥ 319,691$ million. This was primarily due to increases of $¥ 8,185$ million in accounts payable - trade, $¥ 2,765$ million in provision for bonuses, and $¥ 6,707$ million in long-term loans payable, despite a decrease of $¥ 7,161$ million in income taxes payable.
(Net assets)
Net assets as of May 31,2023 decreased by $¥ 5,809$ million compared to the end of the previous fiscal year to $¥ 226,575$ million. This was primarily due to the recording of net income attributable to owners of parent of $¥ 5,126$ million, despite a decrease of $¥ 3,354$ million in retained earnings due to the dividends of surplus.
(3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information

There has been no change from the consolidated financial results forecast announced in the "Consolidated Financial Results for the Fiscal Year Ended February 28, 2023" (on April 10, 2023).

## 2. Quarterly Consolidated Financial Statements and Principal Notes

## (1) Quarterly Consolidated Balance Sheets

|  | As of February 28, 2023 | As of May 31, 2023 |
| :---: | :---: | :---: |
| Assets |  |  |
| Current assets |  |  |
| Cash and deposits | 32,854 | 37,422 |
| Accounts receivable - trade | 54,276 | 56,776 |
| Merchandise | 128,835 | 138,496 |
| Other | 26,740 | 18,061 |
| Allowance for doubtful accounts | (10) | (28) |
| Total current assets | 242,697 | 250,728 |
| Noncurrent assets |  |  |
| Property, plant and equipment |  |  |
| Buildings and structures, net | 107,093 | 108,863 |
| Land | 20,451 | 20,451 |
| Leased assets, net | 51,163 | 50,683 |
| Other, net | 7,132 | 6,716 |
| Total property, plant and equipment | 185,840 | 186,715 |
| Intangible assets |  |  |
| Goodwill | 36,482 | 35,565 |
| Other | 3,765 | 4,274 |
| Total intangible assets | 40,248 | 39,839 |
| Investments and other assets |  |  |
| Guarantee deposits | 47,844 | 48,266 |
| Other | 20,862 | 20,798 |
| Allowance for doubtful accounts | (130) | (80) |
| Total investments and other assets | 68,576 | 68,983 |
| Total noncurrent assets | 294,665 | 295,538 |
| Total assets | 537,362 | 546,266 |


| Liabilities |  |  |
| :---: | :---: | :---: |
| Current liabilities |  |  |
| Accounts payable - trade | 153,182 | 161,368 |
| Short-term loans payable | 12,137 | 12,499 |
| Lease obligations | 10,288 | 10,395 |
| Accounts payable - other | 11,941 | 13,279 |
| Income taxes payable | 10,796 | 3,635 |
| Provision for bonuses | 5,361 | 8,127 |
| Provision for bonuses for directors (and other officers) | 94 | - |
| Contract liabilities | 143 | 134 |
| Other | 12,686 | 15,457 |
| Total current liabilities | 216,633 | 224,897 |
| Noncurrent liabilities |  |  |
| Long-term loans payable | 29,649 | 36,357 |
| Lease obligations | 33,997 | 33,411 |
| Asset retirement obligations | 12,665 | 12,827 |
| Retirement benefits-related liabilities | 7,524 | 7,721 |
| Allowance for executive stock benefit | 781 | 810 |
| Other | 3,724 | 3,664 |
| Total noncurrent liabilities | 88,344 | 94,793 |
| Total liabilities | 304,977 | 319,691 |
| Net assets |  |  |
| Shareholders' equity |  |  |
| Capital stock | 7,747 | 7,748 |
| Capital surplus | 51,681 | 51,682 |
| Retained earnings | 166,566 | 168,338 |
| Treasury stock | $(1,084)$ | $(8,993)$ |
| Total shareholders' equity | 224,909 | 218,775 |
| Accumulated other comprehensive income |  |  |
| Other valuation difference on available-for-sale securities | 373 | 382 |
| Foreign currency translation adjustment | 139 | 158 |
| Accumulated adjustment related to retirement benefits | 327 | 326 |
| Total accumulated other comprehensive income | 840 | 867 |
| Subscription rights to shares | 161 | 158 |
| Minority interests | 6,472 | 6,773 |
| Total net assets | 232,384 | 226,575 |
| Total liabilities and net assets | 537,362 | 546,266 |

## (2) Quarterly Consolidated Statements of Income and Comprehensive Income

## Quarterly Consolidated Statements of Income

Three Months Ended May 31
(Million yen)

|  | For the three months ended May 31, 2022 | For the three months ended May 31, 2023 |
| :---: | :---: | :---: |
| Net sales | 267,716 | 298,267 |
| Cost of sales | 189,284 | 210,457 |
| Gross profit | 78,431 | 87,809 |
| Selling, general and administrative expenses | 70,717 | 80,427 |
| Operating income | 7,713 | 7,381 |
| Non-operating income |  |  |
| Interest and dividend income | 0 | 2 |
| Rental income from real estate | 315 | 375 |
| Sponsorship money income | 218 | 208 |
| Subsidy income | 1,877 | 17 |
| Other | 583 | 865 |
| Total non-operating income | 2,995 | 1,470 |
| Non-operating expenses |  |  |
| Interest expenses | 130 | 179 |
| Share of loss of entities accounted for using equity method | 1 | 63 |
| Rent cost of real estate | 40 | 72 |
| Other | 40 | 10 |
| Total non-operating expenses | 213 | 327 |
| Ordinary income | 10,495 | 8,524 |
| Extraordinary income |  |  |
| Gain on sale of noncurrent assets | 5 | 9 |
| Compensation income | - | 151 |
| Total extraordinary income | 5 | 161 |
| Extraordinary loss |  |  |
| Loss on retirement of noncurrent assets | 10 | 34 |
| Impairment loss | 101 | 8 |
| Loss on store closings | - | 23 |
| Other | 5 | 10 |
| Total extraordinary losses | 118 | 77 |
| Net income before income taxes and minority interests | 10,383 | 8,608 |
| Income taxes - current | 4,549 | 3,622 |
| Income taxes - deferred | (512) | (129) |
| Total income taxes | 4,037 | 3,492 |
| Net income | 6,346 | 5,115 |
| Profit (loss) attributable to non-controlling interests | 24 | (10) |
| Net income attributable to owners of parent | 6,321 | 5,126 |

## Quarterly Consolidated Statements of Comprehensive Income

Three Months Ended May 31
(Million yen)

|  | For the three months ended May 31, 2022 | For the three months ended May 31, 2023 |
| :---: | :---: | :---: |
| Net income | 6,346 | 5,115 |
| Other comprehensive income |  |  |
| Other valuation difference on available-for-sale securities | 1 | 8 |
| Foreign currency translation adjustment | 106 | 37 |
| Remeasurements of defined benefit plans | 10 | (0) |
| Total other comprehensive income | 118 | 45 |
| Comprehensive income | 6,464 | 5,160 |
| Comprehensive income attributable to |  |  |
| Comprehensive income attributable to owners of parent | 6,391 | 5,153 |
| Comprehensive income attributable to non-controlling interests | 72 | 6 |

(3) Notes to Quarterly Consolidated Financial Statements
(Notes on going concern assumption)
Not applicable.
(Notes in case of significant changes in shareholders' equity)
Not applicable.

